AKT1 and hepatocellular carcinoma: As shown in previous studies, we found that treatment with trastuzumab and pertuzumab blocked activation of AKT in sensitive cells T-47D, but did not prevent activation of AKT in two resistant cell lines HCC-1419 [46] and JIMT-1 [46, 47] (Supplementary Figure 3).